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Article info ABSTRACT  
Objectives: To study the effect of hepcidin on the course of chronic 
heart failure with anemia. Methods: 115 patients with CHF caused by 
ischemic heart disease (IHD) were chosen. All of them were treated in 
in-patient conditions and were followed in out-patient conditions. The 
patients were divided into two main and one control groups. Main 
group A consisted of 40 CHF patients with iron deficiency anemia. 
Main group B consisted of 35 CHF patients with anemia of chronic 
disease. 40 CHF patients without anemia were chosen for the control 
group. To patients of the main groups 200mg of Iron (III) hydroxide 
(Venofer®) was administered intravenously once in two days, along 
with standard CHF treatment. Results: Our study found reliable 
increase of serum levels hepcidin in CHF patients with anemia of 
chronic disease compared to CHF patients with iron deficiency anemia 
(45,4%) and control group (33%) (P<0,001). This, in turn, shows that 
hepcidin is an important indicator in differential diagnosis between 
anemia of chronic disease and iron deficiency anemia. Statistical 
analysis of pro-inflammatory cytokines and hepcidin levels was done in 
order to find any associations in patients of our study. Following was 
found: in group B weak positive correlation between hepcidin and IL-1 
(r=0,24 Р<0,05), strong positive correlation between hepcidin and IL-6 
(r=0,52, Р<0,001), and moderate positive correlation between hepcidin 
and TNF-α (r=0,37, Р<0,05). Conclusion: In CHF patients with anemia 
of chronic disease (Group B) hepcidin levels were reliably higher than 
normal ranges and correlation between pro-inflammatory cytokines and 
hepcidin during deterioration of the disease. 
 
Introduction  
Chronic heart failure (CHF) is one of the most signicifant socio-economical 
problems of the healthcare and one of the leading causes of morbidity and mortality 
worldwide [13]. 
Early diagnosis and adequate treatment of aggravating factors, including anemia, is 
important in increasing the quality of life and life expectancy of CHF patients. It was 
found in number of multi-center studies (ELITE II, ValHeFT, COPERNICUS, VEST, 
COMET and others) that prevalence of anemia in CHF varies from 10 to 55%. Anemia is 
viewed as an independent risk factor negatively affecting course, prognosis and 
complications of CHF [18]. SOLVD trial found direct assotiation between hematocrit 
levels CHF. According to 33 month long observation in patients with hematocrit levels of 
40-44, 35-39 and 35%, mortality was respectively 22, 27 and 39% [11]. It was found in a 
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meta-analysis by Groenveld and coauthors that mortality was two times higher in CHF 
patients with anemia compared to the patients with normal hemoglobin levels [14]. In all 
of above mentioned studies criteria of anemia recommended by World Health 
Organisation was used (hemoglobin is <130g/l in men, <120 g/l in women ) [1].  
Etiology and pathogenesis of anemia in CHF is not fully studied [4]. Hemodilution, 
disorders of kidney (cardiorenal anemia syndrome) and iron metabolism, activation of 
pro-inflammatory cytokines (Tumor Necrosis Factor – α (α-TNF), interleukin-6 (IL-6) 
and others) and factors are thought to be the mechanisms of development of anemia in 
CHF [4]. There is also a possibility of drug induced anemia in CHF patients after 
continuous use of angiotensin converting enzyme (ACE) inhibitors and angiotensin 
receptor (AR) blockers (suppression of erythropoiesis) [21].  
Data about the share of different type of anemias in CHF patients varies. According 
to J. Ezekowitz in CHF patients with anemia 21% of cases was due to iron deficiency 
anemia (IDA), other deficiencies – 8%, anemia of chronic disease (ACD) 58% and 13% 
was due to other causes [8]. In a Canadian study conducted on 12065 CHF patients with 
anemia similar results were found (27% iron deficiency, 8% vitamin В12 deficiency, 7% 
folate deficiency, 58% - anemia of chronic disease) [8, 21]. Contrary to them, according 
to Stavros G. Drakos and coauthors share of iron deficiency anemia was 73%, anemia of 
chronic disease - 18,9%, hemodilution - 5,4% and drug induced anemia was 2,7% [19, 
21]. These numbers show that prevalence of anemia among CHF patients, as well as that 
the entire subject itself is not fully studied. 
According to a Polish study decrease of ferritin levels (less than 100mcg/l) and 
ferritin saturation (less than 15% when ferritin is 100-300mcg/l) was found in 101 of 218 
CHF patients (46%). Among the anemic patients 61% had iron deificiency and 43% had 
normal hemoglobin levels [12]. Serum ferritin levels correctly represent iron metabolism 
in reticuloendothelial system, however it is not sensitive in anemia of chronic disease [12, 
15]. 
In recent studies of ACD pathogenesis great attention is given to acute phase protein 
hepcidin, which blocks iron metabolism in different parts of organism, particularly 
enterocytes and macrophages [7, 12]. Correlation was found between the hepcidin and 
liver iron and hemoglobin levels [9, 16]. When there is excess of iron in organism, 
hepcidin production increases under the influence of inflammation factor IL-6 [16]. 
Increased hepcidin levels results in decreased absorbtion of iron from GI tract and 
decreased release of iron from macrophages [11]. Hepcidin suppresses the erithropoesis 
as well [11]. Number of other studies found consistent high levels of hepcidin in anemia 
of chronic disease [3, 5]. But there is not enough available information concerning 
hepcidin levels in CHF patients with anemia. 
As was mentioned before, mortality is two times higher in CHF patients with 
anemia compared to the patients with normal hemoglobin levels [17]. Treatment of 
anemia in the patients results in better quality of life and prolonged life expectancy. 
Therefore, correction of anemia should be included in the treatment complex of CHF 
patients.  
Existence of anemia in CHF worsens the prognosis, considerable decreases life 
quality of patients. Thus, further study of the subject, development of adequate methods 
of correction of anemia along with standard therapy remains actual. 
Methods 
115 patients with CHF caused by ischemic heart disease (IHD) were chosen. All of 
them were treated in in-patient conditions and were followed in out-patient conditions. 
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The patients were divided into two main and one control groups. Main group A consisted 
of 40 CHF patients with iron deficiency anemia. Main group B consisted of 35 CHF 
patients with anemia of chronic disease. 40 CHF patients without anemia were chosen for 
the control group.  
To patients of the main groups 200mg of Iron (III) hydroxide (Venofer®) was 
administered intravenously once in two days, along with standard CHF treatment. 
Control group patients received standard CHF therapy. All patients were observed for six 
months. They were taught about CHF and principles of self-monitoring. 
Diagnosis of CHF and classification of the disease according to functional classes in 
involved patients was made based on patients complaints, anamnesis, clinical 
examination, laboratory and instrumental investigations and New – York Heart 
Association (1964) criteria.  
For classification of anemia World Health Organisation (WHO) criteria were used 
(hemoglobin is <13,0 g/dl in men and <12,0 g/dl in women).  
Inclusion criteria: patients with CHF caused by ischemic heart disease 
Exclusion criteria: Miocardial infarction, unstable angina, arterial hypotonia, severe 
arrythmia, II-III degree AV blocade, congenital heart diseases, stroke, autoimmune and 
diffuse connective tissue diseases, acute inflammation diseases or recurrence of chronic 
inflammation diseases, chronic kidney disease, liver failure, severe bronchial asthma and 
COPD, cancer, psychiatric conditions, alcohol dependence and other severe comorbid 
conditions. 
Laboratory tests. 9ml venous blood was taken from fasting patients. The blood was 
centrifuged for 15 minutes in order to separate serum. Next, in Cobas e601 analysator 
(Germany) hepcidin levels were measured using “BCM diagnostics” protocols, ferritin 
levels - «ORGENTEG» and transferrin using «ELISA» protocols. 
Data analysis. For data processing MS Excel (2013) computer program was used. 
Arithmetic mean and standard deviation (M±m) of all data in following tables were 
calculated. Student’s paired and unpaired t-tests were used to determine significance of 
difference between groups. Correlation analysis was done using Pearson’s correlation 
coefficient and confidence tables.  
Ethical statement. The study was conducted according to scientific research plan of 
Tashkent Medical Academy, within “Development of new methods of diagnosis, 
prophylaxis and treatment of internal diseases” (2015-2017) parameters. Written 
informed consent was taken from all patients before the study. 
Results 
For the study 115 patients with CHF caused by ischemic heart disease were chosen 
from cardiology and cardiorehabilitation departments of Tashkent Medical Academy 
Number 3. Their age was from 50 to 80 years, the mean age was 64,6±4,9 years.  
Hematologic indicators were examined before and after the treatment in order to 
study the influence of anemia in CHF patients and effectiveness of treatment (Table-1). 
Comparative analysis showed differences in hematologic indicators between CHF 
patients with and without anemia, and between patients with anemia of chronic disease 
and iron deficiency anemia. 
In CHF patients with iron deficiency anemia (Group A) before the treatment, mean 
level of hemoglobin was 101,4±3,1 g/l, of ferritin - 85,9±8,5 mcg/l, of transferrin - 
5,2±1,21 g/l, of serum iron - 7,94±0,21 mmol/l and of hepcidin - 10,6±1,3 ng/ml. 
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Table 1 
Changes in hematologic indicators in CHF patient with and without anemia before 
and after treatment 
Indicator Treatment 
Main group 
Р  
Control group 
А group B group 
Without 
anemia 
Hemoglobin, g/l 
Before 101,4±3,1***  104,3±4,8*** >0,05 126,0±6,5 
After 126,6±4,7^^^ 120,1±3,9*^^ <0,05 126,4±5,2 
Hematocrit, % 
Before 35,6±0,62** 34,8±0,82** >0,05 40,9±0,37 
After 40,1±0,19^^ 39,7±0.17*^ >0,05 41,6±0,45 
Erythrocytes, 
·1012/l 
Before 3,6±0,04*** 3,7±0,02** >0,05 4,3±0,04 
After 4,1±0,02^^ 4,0±0,01^ >0,05 4,2±0,05 
Leukocytes 
Before 6,3±0,24 8,9±0,22* <0,05 6,1±0,21 
After 6,0±0,14 7,2±0,12 >0,05 6,3±0,14 
Platelets 
Before 217,8 ±2,98* 229±4,12 >0,05 230,2±2,74 
After 224,6±2,51 231,7±3,79 >0,05 225,2±2,62 
ESR mm/h 
Before 15,7±1,09 21,6±0,75* <0,05 12,5±1,07 
After 11,6±0,33 14,4±0,51 >0,05 11,2±0,53 
ALT 
Before 29,3±1,72 34,0±4,67 >0,05 29,2±1,45 
After 22,6±1,30 30,9±1,60 >0,05 28,2±0,97 
AST 
Before 23,2±1,78 28,7±4,39 >0,05 22,6±1,56 
After 22,5±1,51 26,5±1,68 >0,05 24,6±0,78 
Creatinine, 
mmol/l 
Before 79,9±3,27 77,4±2,46 >0,05 69,9±3,21 
After 78,7±16,4 79,6±0,97 >0,05 72,8±1,31 
Glucose, mmol/l 
Before 5,1±0,32 5,9±0,4 >0,05 5,7±0,4 
After 5,2±0,15 5,0±0,16 >0,05 5,5±0,08 
Serum, mmol/l 
Before 7,94±0,21*** 6,14±1,12*** >0,05 25,8±4,81 
After 22,9±2,8^^ 16,1±2,12*^ <0,05 24,7±3,72 
Ferritin, mcg/l 
Before 
85,9±8,5*** 167,5±8,54 
<0,00
1 
289,5±11,6 
After 318,4±5,46^^^ 259,6±6,5^ >0,05 286,6±10,9 
Transferrin, g/l 
Before 5,2±1,21 6,9±2,28 >0,05 4,1±1,8 
After 3,1±0,14 4,4±0,3 >0,05 3,9±0,10 
Transferrin 
saturation,% 
Before 10,1±8,2** 11,6±6,8* >0,05 26,3±8,6 
After 28,6±8,2^ 22,4±5,2*^ <0,05 30,3±6,9 
Hepcidin ng/ml 
Before 
10,6±1,3 23,3±3,5*** 
<0,00
1 
5,7±1,02 
After 
3,2±0,05 19,2±0,06** 
<0,00
1 
2,7±0,03 
Note: * - differences are significant compared to control group (*- P <0,05, ** - P 
<0,01, *** - P<0,001 
 ^ - differences are significant after treatment compared to before treatment  
(^ - P <0,05, ^^ - P <0,01, ^^^ - P<0,001) 
 
In CHF patients with anemia of chronic disease (Group B) before the treatment, 
mean level of hemoglobin was 104,3±4,8 g/l, of ferritin - 167,6±8,54 mcg/l, of transferrin 
- 6,9±2,28 g/l, of serum iron - 6,14±1,12 mmol/l and of hepcidin - 23,3±3,5 ng/ml. 
4
Central Asian Journal of Medicine, Vol. 2019 [2019], Iss. 3, Art. 11
https://uzjournals.edu.uz/tma/vol2019/iss3/11
Central Asian Journal of Medicine 
uzjournals.edu.uz/tma 85 2019#3 
In CHF patients without anemia (Control group) mean level of hemoglobin was 
126,0±6,5 g/l, of ferritin - 289,5±11,6 mcg/l, of transferrin - 4,1±1,8 g/l, of serum iron 
25,8±4,81 mmol/l and of hepcidin was 7,7±1,02 ng/ml. Changes in hematologic 
indicators of main and control groups are given in Table 1. 
Significant changes in hematologic indicators occurred compared to initial state in 
Group A students after six month of treatment. Hemoglobin levels rose from 101,4±2,1 
g/l to 126,6±4,7 g/l (Р<0,001). In group B patients hemoglobin levels changed from 
104,3±4,8 g/l to 120,1±3,9 g/l (Р<0,01). Moreover, in Group A patients serum iron level 
increased from 7,94±0,21 mmol/l to 22,9±2,8 mmol/l (p<0,01), ferritin from 85,9±8,5 to 
318,4±5,46 (Р<0,001), transferrin from 5,2±1,21 g/l to 3,1±0,14 (Р>0,05). Hepcidin 
levels decreased from 10,6±1,3 ng/ml to 3,2±0,05 ng/ml (P> 0,05). 
In Group B patients serum iron levels increased from 6,14±1,12 mmol/l to 
16,1±2,12 mmol/l (P<0,05), ferritin levels rose from 167,5±8,54 to 259,6±6,5 (Р<0,05), 
transferrin decreased from 6,9±2,28 to 4,4±0,3 (Р>0,05). The study found change in 
serum hepcidin levels from 23,3±3,5 ng/ml to 19,2±0,06 ng/ml (Р>0,05). 
In control group CHF patients without anemia serum iron, ferritin, transferrin 
saturation, transferrin and hepcidin levels were within normal ranges (Table 1). 
The following was found in comparative analysis of laboratory results of CHF 
patients with iron deficiency anemia and anemia of chronic disease. Presence of 
decreased serum iron, ferritin levels and increased transferrin levels in Group A patients 
proves absolute iron deificiency in them. Presence of decreased serum iron levels, 
increased transferrin, and normal amount of iron reserve indicator – ferritin in Group B 
patients suggests functional iron deificiency. Functional iron deificiency is an important 
part of the ACD pathogenesis. While serum ferritin levels correctly represents iron 
reserves in reticular-endothelial system, it is ineffective in evaluation of anemia of 
chronic disease. Recent discovery of acute phase protein – hepcidin that regulates iron 
metabolism gave an insight into pathogenesis of anemia of chronic disease. Our study 
found reliable increase of serum levels in CHF patients with anemia of chronic disease 
compared to CHF patients with iron deficiency anemia (45,4%) and control group (33%) 
(P<0,001). This, in turn, shows that hepcidin is an important indicator in differential 
diagnosis between anemia of chronic disease and iron deficiency anemia. 
Correlation between hepcidin levels and pro-inflammatory cytokines was also 
studied. 
Immune inflammation (i.e. cytokines and reticulo-endothelial cells that regulate iron 
homeostasis, proliferation of erythroid progenitor cells, erythropoietin production, and 
lifespan of erythrocytes) is the basis of pathogenesis of anemia of chronic disease. 
Hypoxic process in organism triggers increased hepcidin production through pro-
inflammatory cytokines [20].  
According to results of our study in control group of CHF patients without anemia 
levels of serum IL-1 were respectively 16,4±0,72 – 18,6±1,93 ng/ml, of IL-6 were 
17,2±1,78 - 18,9±1,3 ng/ml, of TNF-α were 15,9±0,72 – 17,4±1,93 ng/ml in II-III 
functional classes.  
In group А CHF patients with iron deficiency anemia serum levels of IL-1 were 
respectively 17,9±2,1 – 20,8±1,3 ng/ml, of IL-6 were 20,4±1,8 - 22,6±1,3 ng/ml, of TNF-
α were 19,6±0,62 – 21,8±1,64 ng/ml in II-III functional classes.  
In group B CHF patients with anemia of chronic disease serum levels of IL-1 were 
respectively 18,2±0,72 - 21,1±1,93 ng/ml, of IL-6 were 26,6±1,7 - 29,7±1,3 ng/ml, of 
TNF-α were 20,2±0,72 – 24,7±1,93 ng/ml in II-III functional classes (Table 2).  
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Table 2 
Levels of pro-inflammatory cytokines before the treatment 
Indicator 
Main group А 
CHF patients with iron 
deficiency anemia (n=40) 
Main group B 
CHF patients with anemia 
of chronic disease (n=35) 
Control group, CHF 
patients without anemia 
(n=40) 
CHF 
Functional 
class II, n=14 
CHF 
Functional 
class III, 
n=26 
CHF 
Functional 
class II, 
n=12 
CHF 
Functional 
class III, 
n=28 
CHF 
Functional 
class II, 
n=16 
CHF 
Functional 
class III, 
n=24 
IL-1 17,9±2,1 20,8±1,3 18,2±0,72 21,1±1,93* 16,4±0,72 18,6±1,93 
IL-6 20,4±1,8 22,6±1,3* 26,6±1,7** 29,7±1,3***^ 17,2±1,78 18,9±1,3 
α - TNF  19,6±0,62 21,8±1,64* 20,2±0,72* 24,7±1,93** 15,9±0,72 17,4±1,93 
Note: * - differences are significant compared to control group (*- P <0,05, ** - P <0,01, 
*** - P<0,001 
 ^ - differences are significant after treatment compared to before treatment  
(^ - P <0,05, ^^ - P <0,01, ^^^ - P<0,001) 
 
In Group A patients levels of IL-1 were increased to 9,1 – 11,8 % (Р<0,05), of IL-6 
to 18,6 – 19,5 % (Р<0,01), of α - TNF to 23,2–25,0 % (Р<0,01) compared to the control 
group. In Group B patients levels of IL-1 were increased to 10,9 – 13,4 % (Р<0,05), of 
54,6 – 57,1% (Р<0,001), of α - TNF to 27,1–41,0 % (Р<0,01) compared to the control 
group.  
Only part of conducted studies found correlation between hepcidin and pro-
inflammatory cytokines, and data was mostly controversial [6, 19, 22]. Statistical analysis 
of pro-inflammatory cytokines and hepcidin levels was done in order to find any 
associations in Group B patients of our study. Following was found: weak positive 
correlation between hepcidin and IL-1 (r=0,24 Р<0,05), strong positive correlation 
between hepcidin and IL-6 (r=0,52, Р<0,001), and moderate positive correlation between 
hepcidin and TNF-α (r=0,37, Р<0,05). 
Our study found reliable decrease of serum pro-inflammatory cytokines levels in 
CHF patients with iron deficiency anemia and the control group after the treatment. 
Although serum pro-inflammatory cytokines level decreased in Group B CHF patients 
with anemia of chronic disease after the treatment, the levels remained high compared to 
other groups (Table 3).  
In functional class II CHF patients without anemia (control group) there was 
statistically significant decrease in levels of IL-1 from 16,4 to 7,4 ng/ml (p<0,01), IL-6 
from 17,2 to 7,7 ng/ml (р<0,001), α - TNF from 15,9 to 6,8 ng/ml (р<0,001) after the 
treatment. In functional class III CHF patients of the same group levels of IL-1 decreased 
from 18,6 to 8,7 ng/ml (р<0,001), of IL-6 from 18,9 to 8,6 ng/ml (р<0,001), of α - TNF 
from 17,4 to 8,2ng/ml (Р<0,01) after the treatment. 
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Table 3 
Levels of pro-inflammatory cytokines after the treatment 
Indicator Treatment Group А Control group 
CHF 
Functional 
class II, n=12 
CHF Functional 
class III, n=28 
CHF 
Functional 
class II, 
n=16 
CHF 
Functional 
class III, 
n=24 
IL-1 
Before 17,9±2,1 20,8±1,3 16,4±0,72 18,6±1,93 
After  9,6±1,2^^ 10,8±1,23^^^ 7,4±1,3^^ 8,7±0,92^^^ 
IL-6 
Before 20,4±1,8 22,6±1,3* 17,2±1,78 18,9±1,3 
After  10,3±0,98^^^ 12,2±1,43^^^ 7,7±1,43^^^ 8,6±1,2^^^ 
α - TNF  
Before 19,6±0,62 21,8±1,64* 15,9±0,72 17,4±1,93 
After  9,2±1,33^^^ 11,4±1,67^^ 6,8±2,1^^^ 8,2±2,3^^ 
 
  Group B Control group 
IL-1 
Before 18,2±0,72 21,1±1,93* 16,4±0,72 18,6±1,93 
After  16,2±1,12*** 18,3±1,21*** 7,4±1,3^^ 8,7±0,92^^^ 
IL-6 
Before 26,6±1,7** 29,7±1,3*** 17,2±1,78 18,9±1,3 
After  19,7±0,98***^ 22,8±1,32*** 7,7±1,43^^^ 8,6±1,2^^^ 
α - TNF  
Before 20,2±0,72* 24,7±1,93** 15,9±0,72 17,4±1,93 
After  15,6±1,42**^ 19,3± 0,89***^ 6,8±2,1^^^ 8,2±2,3^^ 
Note: * - differences are significant compared to control group (*- P <0,05, ** - P <0,01, 
*** - P<0,001 
 ^ - differences are significant after treatment compared to before treatment  
(^ - P <0,05, ^^ - P <0,01, ^^^ - P<0,001) 
 
In functional class II CHF patients with iron deficiency anemia (Group A) there was 
statistically significant decrease in levels of IL-1 from 17,9 to 9,6 ng/ml (Р<0,01), IL-6 
from 20,4 to 10,3 ng/ml (р<0,001), α - TNF from 19,6 дан 9,2 ng/ml (р<0,001) after the 
treatment. In functional class III CHF patients of the same group levels of IL-1 decreased 
from 20,8 to 10,8 ng/ml (р<0,001), of IL-6 from 22,6 to 12,2 ng/ml (р<0,001), of α - 
TNF from 21,8 to 11,4ng/ml (Р<0,01) after the treatment. 
In functional class II CHF patients with iron deficiency anemia (Group A) IL-1 
levels decreased from 18,2 to 16,2 ng/ml (Р>0,05), IL-6 from 26,6 to 19,7 ng/ml 
(р<0,05), α - TNF from 20,2 to 15,6 ng/ml (р<0,05) after the treatment. In functional 
class III CHF patients of the same group levels of IL-1 decreased from 21,1 to 18,3 ng/ml 
(Р>0,05), of IL-6 from 29,7 to 22,8 ng/ml (Р>0,05), of α - TNF from 24,7 to 19,3ng/ml 
(Р>0,05) after the treatment. 
Discussions 
Comparative analysis of laboratroy results of CHF patients with iron deficiency 
anemia and anemia of chronic disease in our prospective study showed following results. 
Mean level of hemoglobin was 101,4±3,1 g/l in Group A CHF patients with IDA. Mean 
levels of ferritin was 85,9±8,5 mcg/l, of transferrin - 5,2±1,21 g/l, and of serum iron was 
7,94±0,21 mmol/l. Decreased levels of all iron metabolism indicators, particularly the 
serum iron and ferritin that represents iron reserves, proves the presence of overt iron 
deficiency in Group A patients. In Group B CHF patients with anemia of chronic disease 
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mean level of hemoglobin was 104,3 ±5,8 g/l, of ferritin - 167,6±8,5 mcg/l, of transferrin 
- 6,9±2,28 g/l, and of serum iron was 6,14±1,12 mmol/l. The laboratory results of Group 
B patients show that although hemogobin and serum iron levels were decreased, amount 
of ferritin, that represents iron reserves, remained within normal ranges. This suggests the 
presence of functional iron deficiency in the patients. Functional iron deficiency lays on 
the basis of anemia of chronic disease and is caused by inflammation process (cytokines 
and reticulo-endothelial cells that regulate iron homeostasis, proliferation of erythroid 
progenitor cells, erythropoietin production, and lifespan of erythrocytes) [6]. Discovery 
of acute phase protein – hepcidin that affects iron metabolism, enabled the understanding 
of disturbance of iron homeostasis its connection with immune mechanisms in 
pathogenesis of ACD. Increased synthesis of hepcidin occurs in liver under the influence 
of IL-6 and in turn results in decreased absorption of iron from GI tract and blocking of 
iron release from macrophages. This process is the main cause of development ofБу 
жараён CHFда anemia of chronic disease in CHF [18].  
Therefore measuring of hepcidin enables the diagnosis of ACD in patients, 
including CHF patients.  
In Group А CHF patients with IDA serum level of hepcidin was 10,6±1,3 ng/ml. In 
CHF patients with ACD level of hepcidin was 23,3±3,5 ng/ml. In control group CHF 
patients without anemia hepcidin levels were within normal ranges.  
It should be stressed, that differential diagnosis of causes of anemia in CHF in 
hospital conditions is important. Because it is difficult to do adequate prognosis or to 
design optimal treatment tactics without knowing exact cause of anemia. Correction of 
hemoglobin levels is an integral part of treatment of CHF patients. 
There are number of randomized trials on use of erythropoietine with and without 
iron medications in treatment of CHF anemia. According to results of these trials, 
administration of erythropoietine in CHF anemia increases the life quality of patients [2], 
but negatively affects life expectancy [13]. Because of increased risk of thrombosis 
during erythropoietine use, European and the USA associations of cardiologists are 
discouraging the use of these medications in treatment of anemia in CHF patients. 
In our study, intravenous infusion of saccharose complex Iron (III) hydroxide 
(Venofer®) as a part of standard therapy in CHF patients under hospital conditions 
resulted in normalization of hemoglobin levels and replenishment of iron reserves. In 
CHF patients with iron deficiency anemia mean levelof hemoglobin increased from 
101,4±3,1 g/l to 126,6±4,7 g/l (Р<0,001), ferritin and transferrin levels reached normal 
ranges. In CHF patients with anemia of chronic disease hemoglobin levels increased from 
104,3±5,8 g/l to 120,1±3,9 g/l (Р<0,05), ferritin and transferrin levels also reached 
normal ranges. But in the latter group the changes were less visible compared to the first 
group. Comparative analysis of effectiveness of the standard antianemic treatment 
between Groups A and B showed reliable increase of hemoglobin and serum iron levels 
in Group A patients. Although there was increase of hemoglobin and serum levels in 
Group B patients, it was less reliable compared to Group A. 
Follow up after 6 month showed lasting effect of Венофер in Group A patients 
according to laboratory findings. 
As known, cytokines participate in intercellular connection and regulation of 
number of biological processes (hemopoiesis, immune reaction of lymphoid and 
mesenchymal cells, tissue reparation, angiogenesis, inflammationни and others). 
Cytokine induced damage of myocardium is realized through direct toxic effect, 
decreased contractility, increased growth of connective tissue and apoptosis of 
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cardiomyocytes and peripheric muscle cells. Moreover cytokines are one of the causes of 
myocardial hypertrophy and cardiac remodeling. Disruption of endothelium dependent 
arteriole dilation causes high and continuous increase in general peripheric resistance. 
This in turn increases oxygen demand of heart and decreases its contraction. Recently, 
cytokine induced apoptosis of cardiomyocytes is being seen as a fundamental mechanism 
of irreversible changes of cardiac contractility in CHF patients [18]. Lon term effects of 
cytokines include restructuring of intracellular collagen matrix, hypertrophy, dilation and 
myocardial remodeling. Thus, activation of cytokines in CHF negatively affects the 
inotropic function of heart, decreases ejection fraction of left ventricle, increases diastolic 
pressure in heart chambers, limits the physical capabilities of patients and deteriorates the 
disease [12, 18]. 
According to current views, hepcidin secretion increases due to pro-inflammatory 
cytokines, particularly IL-6 [12]. Rise in hepcidin levels blocks the iron export from 
macrophages. Thus macrophages are “closed” and they cannot participate in 
erythropoiesis.  
Moreover, IL-1 and α-TNF decreases concentration of erythropoietin and and 
increases sensitivity of erythropoiesis line to it, causing relative resistance to 
erythropoietin [11, 18].  
The following was found. In functional class II CHF patients without anemia 
(control group) IL-1 level was 16,4±0,72ng/ml, IL-6 was 17,2±1,78 ng/ml, α - TNF was 
15,9±0,72 ng/ml. In functional class III CHF patients of the same group levels of IL-1 
was 18,6±1,93 ng/ml, of IL-6 was 18,9±1,3 ng/ml, of α - TNF was 17,4±1,93 ng/ml. In 
Group A CHF patients with iron deficiency anemia levels of IL-1 were increased 9,1 – 
11,8% (Р<0,05), of IL-6 were 18,6 – 19,5% (Р<0,01), of α - TNF were increased 23,2–
25,0% (Р<0,01) in II and III functional classes respectively. In Group B CHF patients 
with anemia of chronic disease levels of IL-1 were increased 10,9 – 13,4% (Р<0,05), of 
IL-6 were 54,6 – 57,1% (Р<0,001), of α - TNF were increased 27,1–41,0% (Р<0,01) in II 
and III functional classes respectively. 
Correlation between hepcidin and pro-inflammatory cytokines was found only in 
part of conducted studies, and overall data is controversial [12, 20]. 
Statistical analysis of hepcidin levels and pro-inflammatory cytokines of patients in 
or study. Following was found in CHF patients with anemia of chronic disease (Group 
B): weak positive correlation between hepcidin and IL-1 (r=0,24 Р<0,05), strong positive 
correlation between hepcidin and IL-6 (r=0,52, Р<0,05), moderate positive correlation 
between hepcidin and α-TNF (r=0,37, Р<0,05).  
Comparative analysis of of data was done to evaluate effect of standard antianemic 
treatment to cytokine profile in main and control groups.  
In Functional class II CHF patients without anemia (Control group) there was 
reliable (р<0,001) decrease of IL – 1 levels from 16,4 to 7,4 ng/ml, of IL – 6 from 17,2 to 
7,7 ng/ml, of α - TNF from 15,9 to 6,8 ng/ml after the treatment. In functional class III 
CHF patients of the same grop there was reliable (р<0,01) decrease of IL – 1 levels from 
18,6 to 8,7 ng/ml, of IL – 6 from 18,9 to 8,6 ng/ml, of α - TNF from 17,4 to 8,2ng/ml 
after the treatment. This show the effectiveness of standard CHF therapy. 
In Functional class II CHF patients with iron deficiency anemia (Group A) there 
was reliable (р<0,001) decrease of IL – 1 levels from 17,9 to 9,6 ng/ml, of IL – 6 from 
20,4 to 10,3 ng/ml, of α - TNF from 19,6 to 9,2 ng/ml after the treatment. In functional 
class III CHF patients of the same grop there was reliable (р<0,01) decrease of IL – 1 
levels from 20,8 to 10,8 ng/ml, of IL – 6 from 22,6 to 12,2 ng/ml, of α - TNF from 21,8 
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to 11,4ng/ml after the treatment. As these results show, anemia worsens hypoxia, already 
present in CHF patients. Increased hypoxia stimulates the production of pro-
inflammatory cytokines, which in turn damages the myocardium and deteriorates the 
course of CHF. Adequately treated anemia reverses these processes.  
In Functional class II CHF patients with anemia of chronic disease (Group B) there 
was decrease of IL – 1 levels from 18,2 to 16,2 ng/ml, of IL – 6 from 26,6 to 19,7 ng/ml, 
of α - TNF from 20,2 to 15,6 ng/ml after the treatment. In functional class III CHF 
patients of the same grop there was decrease of IL – 1 levels from 21,1 to 18,3 ng/ml, of 
IL – 6 from 29,7 to 22,8 ng/ml, of α - TNF from 24,7 to 19,3ng/ml after the treatment. 
Iron medications were not effective in Group B patients compared to iron deficiency 
anemia patients. Although there was decrease of cytokines after the treatment, their levels 
remained high, compared to other groups. Therefore, revision of treatment strategy of 
CHF patients with anemia of chronic disease is needed.  
Follow up after 6 month showed significant improvement in intracardiac 
hemodynamic indicators in control group and Group B patients. In group B pateints 
although positive changes took place, they were not significant.  
Comparative analysis of main and control groups show, that antianemic treatment 
was effective in CHF patients with iron deficiency anemia where the hematological 
indicators changed positively. In CHF patients with anemia of chronic disease 
effectiveness of antianemic treatment was not reliable. In our opinion, hepcidin levels 
decreased the effectiveness of the treatment. According to the literature of the subject 
there is a positive correlation between iron levels in organism and amount of hepcidin. 
Excessive amounts of iron causes the increased production of hepcidin, which in turn 
blocks the metabolism of the microelement. But no correlation was found between serum 
iron and hepcidin in our study. Moreover, effectiveness of iron medications was not 
proved. 
Conclusion 
In CHF patients with iron deificiency (Group A) and anemia of chronic disease 
(Group B) levels of serum ferritin transferrin, hepcidin were various. In Group B patients 
hepcidin levels were reliably higher than normal ranges (23,3±3,5 ng/ml, р<0,001);  
Results of the study proves that there is difference in laboratory findings between 
iron deficiency anemia and anemia of chronic disease. Measuring of serum levels of 
hepcidin plays an important role in diagnosis of ACD and IDA. 
In functional class II - III CHF patients with anemia of chronic disease levels of 
pro-inflammatory cytokines increase in accordance with the functional class of the 
disease. There was a correlation between pro-inflammatory cytokines and hepcidine 
during deterioration of the disease (r=0,24 Р<0,05 between hepcidin and IL-1, r=0,52, 
Р<0,05 between hepcidin and IL-6, r=0,37, Р<0,05 between hepcidin and TNF-α);  
Systemic hypoxic process, neurohumoral activation of local tissue hormones 
stimulates the expression of pro-inflammatory cytokines, which plays in progression of 
CHF and development of adverse complications. Expression of cytokines positively 
correlates with functional classes of degree of severity of CHF. In patients involved in 
our study cytokine levels increased in accordance with functional class of CHF in both 
main and control groups. In anemic patients (Group A and B) increase was higher 
compared to the control group. 
Serum levels of pro-inflammatory cytokines were increased in CHF patients of all 
groups. The levels were more significant in higher functional classes of CHF, in anemic 
patients, and particularly in patients with anemia of chronic diseaseнинг. It can be 
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concluded that, reason for this is the continuos systemic hypoxia and activation of local 
hormones.  
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